Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | CFTR | P13569 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.39 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.38 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.38 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | GPR139 | Q6DWJ6 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4429494 | 0.87 | KCNN4 (0.44) | KDM4EALDH1A1CFTRSMN1; SMN2MRGPRX4 | |
| SCHEMBL4429636 | 0.86 | SLC6A4 (0.47) | KDM4EALDH1A1CFTRSMN1; SMN2HTT | |
| SCHEMBL4994701 | 0.84 | KDM4E (0.43) | KDM4EALDH1A1CFTRSMN1; SMN2OPRK1 | |
| SCHEMBL4429455 | 0.84 | TSHR (0.44) | KDM4EALDH1A1CFTR | |
| SCHEMBL4995080 | 0.78 | KDM4E (0.41) | KDM4EALDH1A1CFTR | |
| SCHEMBL4993080 | 0.78 | ALDH1A1 (0.41) | KDM4EALDH1A1SMN1; SMN2OPRK1 | |
| SCHEMBL20524639 | 0.77 | PTGS2 (0.51) | KDM4EALDH1A1CFTR | |
| SCHEMBL13306589 | 0.76 | GABRA1 (0.44) | KDM4EALDH1A1SMN1; SMN2CYP3A4MRGPRX4 | |
| SCHEMBL4429492 | 0.76 | KDM5A (0.42) | KDM4EALDH1A1HTTCYP3A4 | |
| SCHEMBL12890135 | 0.75 | ALDH1A1 (0.47) | KDM4EALDH1A1CFTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | ENCYSIVE PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | C3AR1, C5, C5AR1 | KDM4E 2635/4885ALDH1A1 1639/4885CFTR 1414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.